On June 30, 2021, the Interterritorial Council of the National Health System has approved the systems of real-time continuous glucose monitoring (rt-CGM) for inclusion in the Common Package of Benefits for adult patients with type 1 diabetes mellitus and risk of severe hypoglycemia (at least one episode of severe hypoglycemia during the previous year or inadvertent hypoglycemia), who use intensive insulin therapy (multiple daily doses or insulin pump), who require at least six digital punctures a day for self-monitoring of blood glucose and who show adequate motivation to maintain good adherence to the device. The inclusion of rt-CGM devices in the Common Package of Benefits means that these devices are now guaranteed to the defined population nationwide.
See the press release by the Ministry of Health, Consumption and Social Welfare in Spanish here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.